Humacyte Publishes Long-Term Data Assessing Durability Of Symvess In Extremity Arterial Trauma Patients In Journal Of Vascular Surgery Cases, Innovations And Techniques

- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - 

- After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures -

- Results represent first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit -

DURHAM, N.C., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication of new, long-term data assessing the durability of Symvess in extremity arterial trauma patients in the Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT). The study, titled "Long-term Safety and Efficacy Outcomes of the Acellular Tissue Engineered Vessel (ATEV) in Extremity Arterial Trauma Repair" found that Symvess maintained structural integrity over the long term, exhibited low infection rates, and supported high rates of limb salvage in patients followed for up to 36 months.